- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00964015
Starch or Saline After Cardiac Surgery (SSACS)
Short-term Outcomes of Fluid Replacement and Resuscitation Strategy in the Cardiac Surgery Patient: A Randomized, Controlled Trial
When people undergo major surgery, they require intravenous supplementation of fluids for a number of reasons:
- to compensate for no oral intake
- to support blood pressure and organ function during and after surgery
- to replace lost fluid or blood volume
There are a variety of fluid choices doctors have to provide to patients, and it is still not definitively known whether some fluids are better than others in specific situations. This is a particularly interesting question in patients undergoing heart surgery because of the significant volume of fluids used over the entire course of hospitalization, including before the operation, during the operation, and after the operation.
There has been some scientific evidence that the use of starch-based fluids (synthetic colloids) leads to better oxygen delivery to the organs with a smaller volume of fluid given, providing for better recovery from surgery. However, there has also been some scientific evidence that the use of these fluids can harm kidney function. Importantly, none of these large-scale studies were carried out specifically in patients undergoing heart surgery.
The purpose of this study is to answer the question of whether the use of starch-based fluid in the heart surgery patient makes for a safer and faster recovery, causes kidney dysfunction, or makes no discernable difference.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- London Health Sciences Centre
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- patients undergoing elective primary isolated on-pump coronary artery bypass grafting
Exclusion Criteria:
- pregnant patients
- patients with an active intra-cranial bleed
- patients with a history of hypersensitivity to starch solutions
- patients with Stage 4 or 5 Kidney Disease (estimated glomerular filtration rate < 30 ml / min / 1.73 m2)
- patients with a significant preoperative metabolic acidosis, defined by a preoperative capillary blood pH less than or equal to 7.2 and a serum bicarbonate less than 15
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Starch group
Patients randomized to the Starch group will receive Voluven (6% Hydroxyethyl Starch 130/0.4) for their intravenous bolus and fluid resuscitation requirements.
|
|
Aktiv komparator: Saline group
Patients randomized to the Saline group will receive 0.9% Normal Saline for their intravenous fluid bolus and resuscitation requirements
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Incidence of acute kidney injury as defined by RIFLE criteria
Tidsramme: Short term (in hospital, up to 30 days) and mid-term (2 months)
|
Short term (in hospital, up to 30 days) and mid-term (2 months)
|
Maximum postoperative weight gain
Tidsramme: Short-term (in hospital, up to 7 days)
|
Short-term (in hospital, up to 7 days)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Operative mortality
Tidsramme: In hospital (up to 30 days)
|
In hospital (up to 30 days)
|
Duration of ventilation support requirements
Tidsramme: In hospital (up to 30 days)
|
In hospital (up to 30 days)
|
Total chest tube drainage (until removed)
Tidsramme: In hospital (up to 30 days)
|
In hospital (up to 30 days)
|
ICU length of stay
Tidsramme: In hospital (up to 30 days)
|
In hospital (up to 30 days)
|
Transfusion of blood products
Tidsramme: In hospital (up to 30 days)
|
In hospital (up to 30 days)
|
Incidence of atrial fibrillation (necessitating a change in medical management)
Tidsramme: In hospital (up to 30 days)
|
In hospital (up to 30 days)
|
Duration of oxygen supplementation
Tidsramme: In hospital (up to 30 days)
|
In hospital (up to 30 days)
|
Creatinine, Urea, Cr Clearance as estimated by the MDRD formula
Tidsramme: In hospital at defined timepoints, and at 2 months post hospital discharge
|
In hospital at defined timepoints, and at 2 months post hospital discharge
|
Volume of fluid infused
Tidsramme: In hospital (up to 7 days)
|
In hospital (up to 7 days)
|
Total hospital length of stay (when ready to leave tertiary hospital setting)
Tidsramme: In hospital
|
In hospital
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Dave Nagpal, MD, LHSC / UWO
- Hovedetterforsker: Ray Guo, MD, LHSC / UWO
- Hovedetterforsker: Chris Harle, MD, LHSC / UWO
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- LHSC
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Koronar bypass kirurgi
-
Medtronic CardiovascularFullførtArteriosclerosis of coronary artery bypass graftCanada, Forente stater
-
Lawson Health Research InstituteFullførtArteriosclerosis of arterial coronary artery bypass graftCanada
-
Deutsches Herzzentrum MuenchenFullførtArteriosclerosis of arterial coronary artery bypass graftTyskland
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aortic origin of the coronary artery (AAOCA)Italia
-
William Beaumont HospitalsFullførtKoronararteriesykdom | Arteriosclerosis of coronary artery bypass graftForente stater
-
Izmir Bakircay UniversityFullførtMyocardial Bridge of Coronary ArteryTyrkia
-
ITAB - Institute for Advanced Biomedical TechnologiesAzienda Ospedaliero, Universitaria Ospedali RiunitiFullførtMyocardial Bridge of Coronary ArteryItalia
-
Philipps University Marburg Medical CenterFullførtKoronar hjertesykdom | Pasientenes forventninger | Koronararterie Bypass Graft Surgery (CABG)Tyskland
-
Resicardunion nationale de formation et d'evaluation en medecine cardio-vasculaireFullførtHjertefeil | Akutt koronarsyndrom | Koronar bypass-graft Stenose av Native Artery GraftFrankrike
Kliniske studier på 6% Hydroxyethyl Starch 130/0.4
-
Chung-Ang University Hosptial, Chung-Ang University...UkjentSkjoldbruskkjertelektomi | VæskeresponsKorea, Republikken
-
Yonsei UniversityFullførtKoronararterieokklusiv sykdomKorea, Republikken
-
The George InstituteUniversity of Sydney; Fresenius Kabi; Australian and New Zealand Intensive...Fullført
-
B. Braun Melsungen AGFullførtKirurgiTyskland, Østerrike, Tsjekkisk Republikk, Italia, Nederland
-
B. Braun Melsungen AGFullførtReduserte og uspesifikke blodtrykksforstyrrelser og sjokkKina
-
Cliniques universitaires Saint-Luc- Université...Fullført
-
National Institute of Medical Sciences and Nutrition...UkjentOvervekt | Overvekt, sykeligMexico
-
Fresenius KabiB. Braun Melsungen AG; European Society of Anaesthesiology and Intensive...FullførtHypovolemi på grunn av akutt blodtapTyskland, Spania, Frankrike, Tsjekkia, Sør-Afrika, Belgia, Nederland
-
Sifa UniversityUkjentHypotensjon | Anestesi; Bivirkninger, spinal og epiduralTyrkia
-
SangartFullførtVaskulær sykdom | Kritisk iskemi i nedre ekstremiteterSverige